BRAIN ATTACK - AN INDICATION FOR THROMBOLYSIS

被引:5
作者
FAGAN, SC
ZAROWITZ, BJ
ROBERT, S
机构
[1] WAYNE STATE UNIV, COLL PHARM, DETROIT, MI 48202 USA
[2] HENRY FORD HOSP, DEPT PHARM SERV, DETROIT, MI 48202 USA
[3] HENRY FORD HOSP, DEPT NEUROL, DETROIT, MI 48202 USA
关键词
D O I
10.1177/106002809202600114
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: The primary objective of this article is to introduce the reader to the use of thrombolytics in the acute treatment of ischemic stroke. Theory and experimental evidence to support this approach are emphasized in addition to potential adverse effects of thrombolysis. DATA SOURCES: A MEDLINE search was used to identify pertinent literature, including reviews. STUDY SELECTION: Studies were selected for detailed review if they involved stroke patients and addressed possible toxicities of therapy. Any abstracts concerning ongoing clinical trials also were reviewed. DATA EXTRACTION: Data from animal investigations using tissue plasminogen activator for the acute treatment of several models of cerebral ischemia were used to support the importance of early treatment (within six hours of symptom onset). Also, studies performed in animal models of stroke revealed that thrombolysis could be accomplished safely in acute ischemic stroke. All human studies published to date are anecdotal case reports, but point to the safety of thrombolysis if administered early. Reviews of ongoing multicenter trials are taken from published abstracts and proceedings. DATA SYNTHESIS: Thrombolysis holds promise as a hyperacute therapy for acute stroke; however, the risk of intracerebral hemorrhage remains. Crucial to the success of this and any other therapy for acute stroke is the ability to treat patients within hours of symptom onset. Also, the importance of concomitant medications such as heparin and aspirin has not yet been addressed. CONCLUSIONS: Pharmacists need to be knowledgeable of new treatments of stroke and the risks associated with them. As patient educators, pharmacists can contribute to public awareness by promoting the early recognition of stroke symptoms. As pharmacotherapists, pharmacists need to understand the risks and the important monitoring parameters related to thrombolysis. The results of ongoing multicenter clinical trials are awaited before making a final judgement on the usefulness of thrombolysis in acute ischemic stroke.
引用
收藏
页码:73 / 80
页数:8
相关论文
共 70 条
[1]   RATIONALE FOR BOLUS T-PA THERAPY TO IMPROVE EFFICACY AND SAFETY [J].
AGNELLI, G .
CHEST, 1990, 97 (04) :S161-S167
[2]  
ALBERTS MJ, 1991, STROKE, V22, P125
[3]  
[Anonymous], 1990, LANCET, V336, P65
[4]  
[Anonymous], 1989, STROKE, V20, P1407
[5]  
BROOKS J, 1970, J LAB CLIN MED, V76, P879
[6]  
BROTT T, 1990, STROKE, V21, P181
[7]   THE INVESTIGATIONAL USE OF TPA FOR STROKE [J].
BROTT, T ;
HALEY, EC ;
LEVY, DE ;
BARSAN, WG ;
REED, RL ;
OLINGER, CP ;
MARLER, JR .
ANNALS OF EMERGENCY MEDICINE, 1988, 17 (11) :1202-1205
[8]  
BROTT T, 1988, STROKE, V19, P133
[9]  
BROTT T, 1990, FIBRINOLYSIS CENTRAL, P189
[10]   TREATMENT OF CEREBROVASCULAR THROMBOSES AND EMBOLISM WITH FIBRINOLYTIC AGENTS [J].
CLARKE, RL ;
CLIFFTON, EE .
AMERICAN JOURNAL OF CARDIOLOGY, 1960, 6 (02) :546-549